Trulicity Injection, Solution
Product Images NDC 50090-5467

Product Visual Gallery

This gallery contains 46 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-5467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905467)

Trulicity 3 mg/0.5 mL Dulaglutide Injection solution label from A-S Medication Solutions. The single-dose pen contains 3 mg of dulaglutide per 0.5 mL for subcutaneous injection. Storage instructions specify refrigeration at 36 to 46 degrees F, protecting the product from light, and no freezing.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites V1)

An anatomical illustration showing recommended subcutaneous injection sites on the human body for Trulicity (dulaglutide) injection. Marked areas in yellow include the abdomen, front and outer thigh, back of the arms, and upper buttocks/lower back on both front and back views of the body.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites V1)

An anatomical illustration showing recommended subcutaneous injection sites on a human figure from front and back views. Highlighted areas include the abdomen around the navel, outer upper arms, and front and back of the thighs. These sites are relevant for administration of Trulicity (dulaglutide) injection solution.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites V1)

An illustration showing recommended subcutaneous injection sites for Trulicity (Dulaglutide) on a human body. The front view highlights the abdomen, thigh, and upper arm areas, while the back view emphasizes the upper arm and upper buttocks regions as injection sites.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites V1)

An instructional diagram showing recommended injection sites for Trulicity (Dulaglutide) subcutaneous injection. The image depicts front and back views of a human figure with highlighted areas for injection including the abdomen, outer thigh, and upper arm.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

Trulicity 3 mg/0.5 mL injection solution, subcutaneous, packaged in a prefilled pen. The label shows the brand name Trulicity, active ingredient Dulaglutide, and dosage strength. It is labeled by A-S Medication Solutions with product NDC 50090-5467.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

An instructional illustration showing a subcutaneous injection pen with an arrow pointing to the expiration date area on the device. The image highlights where to locate the expiration date information on the Trulicity injection pen.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

Trulicity 3 mg/0.5 mL injection, solution in a single-dose prefilled pen for subcutaneous use, labeled by A-S Medication Solutions. The image shows the pen with a white body and green label area, featuring dosage and branding information.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

A purple instructional illustration showing a hand being rinsed under running water drops, symbolizing handwashing or washing of a surface with water.*

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

An instructional illustration showing a hand holding a Trulicity injection pen vertically and another hand holding the pen cap below it, with a downward arrow indicating the removal of the pen cap from the injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing hands preparing a prefilled injection pen for use, depicting the removal of a green cap before subcutaneous administration. The image appears to demonstrate step-by-step handling of an injection device, likely related to Trulicity (dulaglutide) 3 mg solution for injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration showing hands holding an injection pen for subcutaneous use, with a timer icon indicating 5-10 seconds for an injection step, and a zoomed-in view of a component of the device, likely indicating a dosage or needle feature. The image relates to the use of Trulicity (dulaglutide) injection, solution.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An illustration showing a hand holding a prefilled syringe filled with medication above a biohazard sharps disposal container. The image suggests the proper disposal of the injection device after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An instructional diagram of a Trulicity injection pen, showing labeled parts including the injection button at the top, lock ring, indicator with lock/unlock symbols, the medicine reservoir visible inside, clear base, and the base cap at the bottom where the needle end is located.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

Trulicity 3 mg/0.5 mL injection, solution in a prefilled injectable pen labeled with the brand and generic name Dulaglutide. The pen features a yellow body with white and purple accents and is designed for subcutaneous use. Manufactured by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

An illustrated instructional diagram showing two hands preparing an injection device. One hand holds a pen-like injector with a green cap, and the other hand holds a black circular cap being removed or attached with a downward arrow indicating action. The image appears to guide the user on assembling or preparing the injection device before use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing a person administering a subcutaneous injection using a prefilled syringe. The image emphasizes proper hand placement and a twisting motion to remove or adjust a component before injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

Instructional illustration showing a hand holding an injection device, indicating a step in preparing or administering a subcutaneous injection. A highlighted close-up features the plunger movement inside the syringe, with a timing indication of 5-10 seconds for a particular step.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An instructional illustration showing a hand disposing of a used injection pen into a biohazard sharps container. The image emphasizes proper disposal of the Trulicity injection device to prevent exposure to used needles or medical waste.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

Illustration of a Trulicity (Dulaglutide) 3 mg/0.5 mL injection pen labeled with parts including Injection Button, Lock Ring, Indicator, Lock/Unlock, Medicine reservoir, Clear Base, and Base Cap. The diagram shows the pen's orientation with the top injection button and the bottom needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

Trulicity 3 mg/0.5 mL injection, solution in a prefilled, single-use pen device. The pen is primarily white with a green dosing button end and a clear cap on the needle end. It features a purple and blue label band near the center. Labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

Instructional illustration showing a hand holding a prefilled injection pen for Trulicity (Dulaglutide) and connecting it to a black component below, indicated by a downward arrow, likely depicting part of the medication preparation or injection process.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

An instructional illustration showing hands removing or twisting the cap of a prefilled injection pen, likely for subcutaneous administration. The image includes a green lock icon indicating the device is being unlocked or prepared for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

An instructional diagram demonstrating the subcutaneous injection process for Trulicity (Dulaglutide). It shows hands holding the injection device at the abdominal area, with an inset highlighting the gray plunger visible to indicate injection completion. Text notes that the injection should take 5-10 seconds and completion is confirmed when the gray plunger is visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

An illustration showing a hand holding a prefilled syringe with a flow control indicator and needle guard, poised above a biohazard sharps container. The syringe likely represents the Trulicity 3 mg/0.5 mL subcutaneous injection solution. The image depicts proper disposal of the used injection device into the biohazard container.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional diagram of a Trulicity 3 mg/0.5 mL injection pen, showing labeled parts including the injection button, lock ring, indicator, lock/unlock switch, medicine chamber, clear base, and base cap, oriented from top to needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

Trulicity 3 mg/0.5 mL injection, solution in a prefilled pen for subcutaneous use. The image shows the pen device with a clear chamber for medication, a purple and white label section, and a green cap at the end. The label includes small icons in red and green, and the pen has a gray base at the opposite end from the cap.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional diagram showing a two-handed technique for assembling or preparing a Trulicity injection pen. One hand holds the injection device upright while the other hand holds a separate black component below, with an arrow indicating to connect or insert it downward.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

Instructional illustration showing the proper technique for administering a subcutaneous injection using an injectable pen device, with emphasis on rotating or turning a component of the pen before injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional illustration showing the process of administering a subcutaneous injection using a Trulicity (dulaglutide) injection pen. It includes a close-up view of the pen's gray plunger and text indicating that the injection is complete when the gray plunger is visible, with a recommended injection duration of 5 to 10 seconds.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

An illustration depicting a hand holding an injection syringe above a biohazard sharps disposal container. The syringe appears to be prepared for disposal, indicating safe disposal practices for injectable medications like dulaglutide injection solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

Illustration of a Trulicity (dulaglutide) injection pen showing labeled parts including Injection Button, Lock Ring, Indicator, Lock/Unlock symbol, Medicine chamber, Clear Base, and Base Cap. The orientation is indicated with arrows for Top and Bottom/Needle End.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

Trulicity 3 mg/0.5 mL injection, solution in a pre-filled pen for subcutaneous use. The pen features a white and green label with a purple accent near the injection end. Manufactured by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional diagram showing a folded paper sheet with arrows indicating to unfold and lay it flat. Text below advises reading both sides for full instructions, likely part of medication use or packaging insert guidance.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

Trulicity 3 mg/.5 mL injection, solution in a prefilled pen syringe for subcutaneous use, labeled by A-S Medication Solutions. The packaging is predominantly purple with white text, showing the product name and strength.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A forest plot chart displaying pharmacokinetic (PK) parameters AUC and Cmax ratios with 90% confidence intervals relative to reference across different intrinsic factors such as weight, age, sex, ethnicity, and varying degrees of renal and hepatic impairment. The horizontal axis represents the ratio relative to reference values from 0.0 to 2.0.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A pharmacokinetic chart titled 'Ratio and 90%CI' showing the effect of coadministered drugs on the area under the curve (AUC) and maximum concentration (Cmax) relative to a reference. The chart lists multiple drugs including Lisinopril, Metoprolol, Digoxin, Norelgestromin/Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin, with plotted ratios and confidence intervals on a horizontal axis ranging from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V1)

A line graph depicting the least squares mean HbA1c (%) over 52 weeks post-randomization, comparing Trulicity 1.5 mg, Trulicity 0.75 mg, Sitagliptin 100 mg, and placebo. The x-axis shows weeks post-randomization, and the y-axis shows LS mean HbA1c (%) values. Sample sizes for each group at different time points are listed below the graph.*

FDA Label Image

Figure 5 (Trulicity Pi F4 V1)

A line graph comparing LS Mean HbA1c (%) over 26 weeks post-randomization for TRULICITY 1.5 mg, TRULICITY 0.75 mg, Exenatide, and Placebo. The graph shows a decrease in HbA1c levels over time with different treatment groups, with the x-axis representing weeks and the y-axis representing HbA1c percentage. Sample sizes at baseline and week 26 are included below the graph.*

FDA Label Image

Figure 6 (Trulicity Pi F5 V1)

A Kaplan-Meier survival curve comparing the percentage of patients with an event over time (years) between Dulaglutide and placebo groups. The graph shows two lines, with the Dulaglutide line below the placebo line, indicating fewer events over approximately 6 years. Patient counts at risk are listed below the x-axis for both groups at various time points.*

FDA Label Image

Figure 4 (Trulicity Pi F6 V1)

A line graph displaying mean HbA1c (%) levels over time (weeks post-randomization) for three doses of Trulicity (Dulaglutide): 1.5 mg, 3 mg, and 4.5 mg. The graph shows data from baseline to week 36, including the number of subjects with observed data at baseline and week 36 for each dose group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.